Conference call to discuss recent FDA breakthrough therapy designation and Phase 3 clinical plans to be held on March 21 at 11 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENSC:
- Ensysce Biosciences reports Q4 EPS ($1.13) vs. ($18.30) last year
- Ensysce Biosciences receives positive Nasdaq listing determination
- Ensysce Biosciences completes meeting with FDA for PF614-MPAR
- Ensysce Biosciences announces publication of clinical bioequivalence manuscript
- Ensysce Biosciences Secures Funding and Expands Shareholder Value